Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA4 | P22748 | 3/20 | 0.31 |
| ▸ | CA7 | P43166 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18491389 | 0.73 | — | — | |
| SCHEMBL7016048 | 0.72 | GPR3 (0.32) | GPR3ELANE | |
| SCHEMBL3714644 | 0.69 | CA12 (0.35) | GPR3KMT2AMEN1NOX1CA12 | |
| SCHEMBL9782263 | 0.66 | GPR3 (0.31) | GPR3 | |
| Methane SCHEMBL28249298 | 0.66 | GPR3 (0.67) | GPR3KMT2AMEN1NOX1CA12 | |
| SCHEMBL2520640 | 0.64 | MEN1 (0.34) | KMT2AMEN1NOX1CA12CA1 | |
| SCHEMBL2376272 | 0.63 | GPR3 (0.42) | GPR3KMT2AMEN1NOX1CA12 | |
| SCHEMBL11036902 | 0.63 | GPR3 (0.55) | GPR3KMT2AMEN1NOX1CA12 | |
| SCHEMBL88079 | 0.62 | — | — | |
| SCHEMBL30951022 | 0.62 | GPR3 (0.71) | GPR3KMT2AMEN1NOX1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | claimed |
| EP-3938362-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-19 | — | — | EP | claimed |
| CN-113166110-A | 2-aminopyrimidine compounds and application thereof | 暨南大学 | 2021-07-23 | — | — | CN | claimed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | claimed |
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | claimed |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | CEPHALON, INC. (US) | 2009-03-05 | — | — | US | claimed |
| US-7449481-B2 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2008-11-11 | — | — | US | claimed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | claimed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | claimed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| JP-2002539201-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| US-5461072-A | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | BURROUGHS WELLCOME CO. (US) | 1995-10-24 | — | — | US | claimed |
| EP-0543855-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003130-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-05 | — | — | WO | claimed |
| WO-1990001929-A1 | NEW MEDICAL USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-03-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | GPR3 2278/4885KMT2A 3564/4885MEN1 4240/4885 |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | AANAT, SNCA, NAT1 | GPR3 894/4885KMT2A 630/4885MEN1 4433/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | GPR3 1787/4885KMT2A 2974/4885MEN1 1164/4885 |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | GLP1R, GIPR, GCGR | GPR3 65/4885KMT2A 4286/4885MEN1 1203/4885 |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | GPR3 96/4885KMT2A 2742/4885MEN1 639/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | GPR3 3541/4885KMT2A 3705/4885MEN1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.